Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Ultragenyx Pharma (RARE) Misses Q4 EPS by 45c
February 10, 2022 4:30 PM ESTUltragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.79), $0.45 worse than the analyst estimate of ($1.34). Revenue for the quarter came in at $83.4 million versus the consensus estimate of $83.79 million.
GUIDANCE:
The company expects 2022 revenue for Crysvita in Ultragenyx territories to be... More
